Global Neurology Academy
The Global Neurology Academy (GNA) Series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.
For more information about GNA, visit www.globalneurologyacademy.org.
Episodes 1-15 of 30
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
CME/CEOptimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
CME/CEAre All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
CME/CEMechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
Advances in the Treatment of Neuropsychiatric Symptoms of Alzheimer's Disease: Early Recognition, Diagnosis, and Innovative Emerging Therapies
CME/CEAdvances in the Treatment of Neuropsychiatric Symptoms of Alzheimer's Disease: Early Recognition, Diagnosis, and Innovative Emerging Therapies
Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
CME/CETreatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics
- advertisement
Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
CME/CETreatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
Living with gMG: Navigating Personal, Professional, and Mental Health Challenges
MinuteCE®Living with gMG: Navigating Personal, Professional, and Mental Health Challenges
Diagnostic Advances in gMG: Effective Tools and Techniques
MinuteCE®Diagnostic Advances in gMG: Effective Tools and Techniques
Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management
MinuteCE®Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management
A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained
MinuteCE®A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained
New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy
MinuteCE®New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy
- advertisement
Managing Side Effects in FcRn Therapy: Best Practices for gMG
MinuteCE®Managing Side Effects in FcRn Therapy: Best Practices for gMG
Ocular to Generalized MG: How and Why the Disease Evolves
MinuteCE®Ocular to Generalized MG: How and Why the Disease Evolves
Preventing Myasthenic Crisis: Early Signs and Critical Interventions
MinuteCE®Preventing Myasthenic Crisis: Early Signs and Critical Interventions
